REGULATED INFORMATION

GHENT, Belgium, 10 November 2009  - Ablynx [Euronext Brussels:  ABLX]
today provides its non-audited business update in compliance with the
EU transparency directive. This report summarises material events and
Ablynx's financial position  for the  third quarter of  2009. It  has
been approved by the Board of Directors.

Q3 2009 Highlights

  * Initiated an open-label, randomised Phase II study of its
    anti-thrombotic Nanobody®, ALX-0081, in patients undergoing
    percutaneous coronary intervention (PCI)
  * Announced positive results from its double-blind, randomised,
    placebo-controlled Phase I study with ALX-0681, a subcutaneous
    formulation of its novel anti-thrombotic Nanobody
  * Received a milestone payment of $4 million as Wyeth
    Pharmaceuticals initiated a Phase II multiple dose study of an
    anti-TNFa Nanobody in patients with rheumatoid arthritis
  * Increased revenues by 133% to €21.9 million for the period
    January-September (2008: €9.4 million)
  * €93.7 million in cash at 30 September 2009

Business Update
Revenues increased  over  the first  nine  months by  133%  to  €21.9
million compared with the same  period in 2008 (2008: €9.4  million).
Expenses increased by 46% to €37.5 million (2008: €25.6 million). The
net loss for the first nine  months of 2009 was €13.5 million  (2008:
€12.1 million).  The  Company's  total cash  position(*)  was  €93.7M
 million at 30 September 2009 (2008: €119.8 million).

(*) The Company's cash position is composed of cash, cash equivalents
and financial assets available-for-sale.

Material events after 30 September 2009
On 12 October, Ablynx reached a settlement with Domantis, part of the
GlaxoSmithKline group of companies, concerning a dispute relating  to
a settlement  agreement which  Ablynx and  Domantis entered  into  in
2005. Under the terms of the  agreement Ablynx received a license  to
the European Winter II patent and will pay Domantis low  single-digit
royalties  on   the   first   five  Nanobody   products   which   are
commercialised.


For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Dr John McIntyre
t:   +44 (0)20 7866 7857
f:   +44 (0)20 7866 7900
e:  ablynx@collegehill.com

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com

Wim Ottevaere
Chief Financial Officer
t:   +32 (0)9 262 00 08
e:  wim.ottevaere@ablynx.com

hugin.info/137912/R/1354059/328135.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.